نمایش پرونده ساده آیتم

dc.contributor.authorYousefi, B
dc.contributor.authorZarghami, N
dc.contributor.authorSamadi, N
dc.contributor.authorMajidinia, M
dc.date.accessioned2018-08-26T07:40:56Z
dc.date.available2018-08-26T07:40:56Z
dc.date.issued2016
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/47318
dc.description.abstractDevelopment of resistance in cancer cells results in a high failure rate in cancer chemotherapy in the clinic. Therefore, investigating the mechanisms by which cancer cells acquire the capability to avoid cell death upon exposure to antineoplastic agents is of great significance in cancer research. In this review article, we will provide an overview of the mechanisms and molecular machinery of drug resistance in cancer cells which include but may not be limited to altered membrane transport and drug metabolizing enzymes, genetic response, enhanced DNA repair and alternation in the target molecules. A special focus will be on describing the strategies and the rationale for exploitation of peroxisome proliferator-activated receptors for overcoming the observed resistance in cancer cells.
dc.language.isoEnglish
dc.relation.ispartofANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
dc.subjectCancer
dc.subjectchemotherapy
dc.subjectdrug resistance
dc.subjectPPARs
dc.subjectP-glycoprotein
dc.subjectthiazolidinedione
dc.titlePeroxisome Proliferator-Activated Receptors and their Ligands in Cancer Drug-Resistance: Opportunity or Challenge
dc.typeReview
dc.citation.volume16
dc.citation.issue12
dc.citation.spage1541
dc.citation.epage1548
dc.citation.indexWeb of science
dc.identifier.DOIhttps://doi.org/10.2174/1871520616666160204112941


فایلهای درون آیتم

فایلهاسایزفرمتنمایش

هیچ فایل مرتبطی وجود ندارد

این آیتم در مجموعه های زیر مشاهده می شود

نمایش پرونده ساده آیتم